Amgen (BRSE:000907582) - Aandelenkoers, Nieuws & Analyse

000907582 Overzicht aandelen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Meer informatie

000907582 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	5/6
Financiële gezondheid	2/6
Dividenden	5/6

Beloningen

Verhandeld tegen 49% onder onze schatting van de reële waarde

De winst zal naar verwachting met 5.73% per jaar groeien

De winst groeide het afgelopen jaar met 10.7%

Betaalt een betrouwbaar dividend van 3.13%

Risicoanalyse

Aandelen zijn zeer illiquide

De schulden worden niet goed gedekt door de operationele kasstroom

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Amgen Inc. Concurrenten

Novartis

SWX:NOVN

CHF 187.3b

Roche Holding

SWX:ROG

CHF 204.3b

Lonza Group

SWX:LONN

CHF 37.7b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$79.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Amgen
Historische aandelenkoersen
Huidige aandelenkoers	US$226.36
52 Week Hoogtepunt	US$240.08
52 Week Laag	US$198.51
Bèta	0.58
11 maand verandering	0%
3 maanden verandering	-0.51%
1 Jaar Verandering	n/a
33 jaar verandering	25.87%
5 jaar verandering	11.40%
Verandering sinds IPO	186.53%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	000907582	CH Biotechs	CH Markt
7D	0%	-1.4%	0.6%
1Y	n/a	105.2%	5.8%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 000907582 presteerde ten opzichte van de Swiss Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 000907582 presteerde ten opzichte van de Swiss markt.

Prijsvolatiliteit

Is 000907582's price volatile compared to industry and market?
000907582 volatility
000907582 Average Weekly Movement	n/a
Biotechs Industry Average Movement	12.7%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	1.6%

Stabiele aandelenkoers: 000907582 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 000907582 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1980	25,200	Bob Bradway	www.amgen.com

Amgen Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Amgen zich tot de beurswaarde?
000907582 fundamentele statistieken
Marktkapitalisatie	CHF 126.76b
Inkomsten(TTM)	CHF 6.58b
Inkomsten(TTM)	CHF 23.33b

19.3x

Koers/Winstverhouding

5.4x

P/S-verhouding

Is 000907582 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
000907582 resultatenrekening (TTM)
Inkomsten	US$26.83b
Kosten van inkomsten	US$7.05b
Brutowinst	US$19.78b
Overige uitgaven	US$12.22b
Inkomsten	US$7.57b

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	14.14
Brutomarge	73.73%
Nettowinstmarge	28.20%
Schuld/Eigen Vermogen Verhouding	789.8%

Hoe presteerde 000907582 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.1%

Huidig dividendrendement

59%

Uitbetalingsratio

000907582 Overzicht aandelen

Beloningen

Risicoanalyse

Amgen Inc. Concurrenten

SWX:NOVN

CHF 187.3b

SWX:ROG

CHF 204.3b

SWX:LONN

CHF 37.7b

NasdaqGS:REGN

US$79.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Recent updates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Announces Otezla®? (Apremilast) Now Available in the U.S. for Moderate to Severe Plaque Psoriasis

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Insider recently sold CHF2.2m worth of stock

Upcoming dividend of US$2.13 per share at 3.3% yield

Amgen Inc. Announces Management Changes

Second quarter 2023 earnings released: EPS: US$2.58 (vs US$2.46 in 2Q 2022)

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Amgen Inc. Samenvatting

19.3x

5.4x

Inkomsten en omzet

Dividenden

3.1%

59%